Needham Rates Revolution Medicines (RVMD) Buy, $275 Price Target

Needham has reiterated its Buy rating on Revolution Medicines, Inc. (RVMD) with a price target of $275 on October 15, 2026. This target remains unchanged from its prior assessment.

Other Institutional Activity in Revolution Medicines

Several other institutional investors have been active in Revolution Medicines. Blackrock Inc. grew its holdings by 2,483,518 shares, ending with 13,695,790 shares worth about $2.44 billion. FMR, LLC added 3,736,136 shares, bringing its total to 12,200,422 shares valued at approximately $2.17 billion. Meanwhile, Baker Bros. Advisors, LP increased its stake by 1,888,116 shares, totaling 11,443,357 shares valued at around $2.04 billion.

Revolution Medicines, Inc. Stock Down 4.7%

The stock recently traded around $182.01, which is significantly lower than Needham's price target of $275. This places the stock about 33.8% below the target, indicating potential upside if the market aligns with the analyst's expectations.

Recent Earnings

Revolution Medicines reported a trailing twelve-month EPS of -$8.87, reflecting its current status as a clinical-stage company. The next earnings report is scheduled for November 4, 2026, which could provide further insights into its financial health.

Insider Buying and Selling at Revolution Medicines, Inc.

Recent insider transactions include Elizabeth M. Anderson, a Director, who sold 10,143 shares on September 22, 2026, valued at approximately $1.96 million. Anthony Mancini, an Officer, sold 3,708 shares on September 25, 2026, worth about $743,285. Additionally, General Counsel Jeffrey Todd Cislini sold 765 shares at an average price of $207.32, totaling $158,600 on the same day. Officer Alan B. Sandler also sold 6,309 shares on September 29, 2026, valued at approximately $1.28 million.

Analysts Set New Price Targets

On October 15, 2026, Needham reiterated its Buy rating on Revolution Medicines with a target of $275. Earlier, Brookline Capital initiated coverage with a Buy rating and a target of $318 on September 28, 2026. Truist Securities maintained a Buy rating with a target of $240 on October 7, 2026, while RBC Capital has maintained an Outperform rating with targets of $259 and $260 on October 8 and 14, 2026, respectively.

About Revolution Medicines

Revolution Medicines, Inc. is a clinical-stage precision oncology company based in Redwood City, California. It focuses on developing targeted therapies for cancers driven by mutations in the RAS gene. The company is working on various treatments that aim to inhibit RAS-driven cancers, which could be crucial for patients with limited treatment options.

Bottom Line

Investors should keep an eye on Revolution Medicines as it approaches its next earnings date on November 4, 2026. With several analysts maintaining strong ratings and targets above the current trading price, further developments could impact the stock's trajectory.